CLLS Nov 2024 2.500 call
- GlobeNewswire
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing. TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE
- Zacks
Cellectis (CLLS) Upgraded to Buy: Here's Why
Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
The heavy selling pressure might have exhausted for Cellectis (CLLS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
